- Home
- CRBP
as 06-20-2025 3:33pm EST
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NORWOOD |
| Market Cap: | 73.4M | IPO Year: | N/A |
| Target Price: | $53.56 | AVG Volume (30 days): | 123.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.64 - $61.90 | Next Earning Date: | 08-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 150.03% |
Stock Insider Trading Activity of Corbus Pharmaceuticals Holdings Inc. (CRBP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Altmeyer Anne | CRBP | Director | May 30 '25 | Sell | $7.25 | 1,392 | $10,095.62 | 1,391 | |
| Jenkins John Kenneth | CRBP | Director | May 30 '25 | Sell | $7.35 | 2,783 | $20,465.35 | 33 |
Latest Corbus Pharmaceuticals Holdings Inc. News
CRBP Breaking Stock News: Dive into CRBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
MT Newswires
a month ago
Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating
MT Newswires
a month ago
Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating
GlobeNewswire
a month ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
GlobeNewswire
a month ago
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference
MT Newswires
a month ago
RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk
Associated Press Finance
2 months ago
Corbus Pharmaceuticals: Q1 Earnings Snapshot
GlobeNewswire
2 months ago
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Compare CRBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRBP Corbus Pharmaceuticals Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.